At the news
? MIXEDIMPACT 7/10 8-K filed Feb 25, 2026 at 16:10 ET
Sarepta Therapeutics reported mixed financial results for 2025, with full-year revenue growing 16% to $2.20 billion driven by ELEVIDYS and collaboration revenue, but Q4 revenue declining 33% due to suspended shipments of ELEVIDYS to non-ambulatory patients. The company strengthened its financial position through debt refinancing and expects to remain profitable and cash-flow positive in 2026, while advancing its pipeline including positive three-year ELEVIDYS data and Japan launch.
- Full-year 2025 revenue was $2.198 billion, up 16% YoY, driven by $77.9 million increase in ELEVIDYS net product revenue and $219.9 million in higher collaboration revenue
- Q4 2025 revenue was $442.9 million, down 33% YoY, primarily due to $273.8 million less in ELEVIDYS net product revenue after suspending shipments to non-ambulatory patients
- GAAP net loss was $713.4 million for 2025 vs. $235.2 million profit in 2024, with Q4 2025 GAAP net loss of $412.2 million vs. $159.0 million profit in Q4 2024
- Cash, cash equivalents, restricted cash and investments were $953.8 million as of December 31, 2025, down from $1.50 billion as of December 31, 2024
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access